Latest Clinical research Stories
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD...
Unexpected drug toxicities occurring years after prescription drug approval MCLEAN, Va., May 21, 2013 /PRNewswire/ -- In the last ten years, many people have developed unexpected toxicities from prescription drugs that had been on the market for several years. Researchers have been baffled. Dr. Dorothy L. Smith, a leading expert in the development of patient adherence programs, suggests unexpected toxicities could occur when patients in real-life have better patient adherence than...
PHILADELPHIA, May 21, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical...
- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p
HASSELT, Belgium, May 21, 2013 /PRNewswire/ -- Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies(TM), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below. Dr Vaeck will highlight Complix' recent progress in applying its...
Clinical Data on CERE-120 (AAV-NRTN) Presented at the 16th Annual Meeting of the American Society of Gene and Cellular Therapy (ASGCT) SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. This exploratory...
According to a recent medical study, various forms of dietary supplements have been found to be the culprit of more than 50 percent of the Food and Drug Adminstration’s (FDA) Class I Pharmaceutical recalls between 2004 and 2012. Kiley Law Group defective product attorneys comment on massive recalls and the damage the affects have on consumer health and trust. Andover, Massachusetts (PRWEB) May 20, 2013 According to a recent medical study (Jama Internal Medicine April 15, 2013), various...
A recent CBS News article explores various proposed steps to increase the safety of indoor tanning salons. Dr. Simon Ourian of Epione Beverly Hills says that the FDA proposals are long overdue. Los Angeles, CA (PRWEB) May 20, 2013 According to a May 6, 2013 CBS News article, titled “FDA Wants Cancer Warnings at Indoor Tanning Salons,” tanning salons in the US may soon have to face stricter safety regulations. The Food and Drug Administration wants to see cancer warnings on indoor...
Companies Announce Partnership to Improve the Quality and Efficiency of Clinical Trials at the CenterWatch Forum on Optimizing Clinical Research Performance in Boston, MA PRINCETON, N.J., May 20, 2013 /PRNewswire/ -- The WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for human research, announced today that it has partnered with Mytrus, Inc., a pioneer in "virtual clinical trials" and technologies that improve clinical trial efficiency,...
WELLINGTON, Fla., May 20, 2013 /PRNewswire/ -- Embark Holdings, Inc. (OTC: EMBK) announces that its wholly owned subsidiary Muscle Warfare, Inc. has passed a recent FDA inspection entitled an EIR (Establishment Inspection Report). The inspection was conducted to confirm that Muscle Warfare had discontinued the use of DMAA as stated in a response letter dated back to May of 2012. The inspection also included a complete facility inspection, which reviewed written and executed standard...
